skip to content

Department of Veterinary Medicine

Cambridge Veterinary School


I gradated from School of Pharmacy, Mansoura University, Egypt then in 2004, I completed my MSc in Microbiology and Immunology at the Microbiology Department in the same school. In 2009, I completed my PhD in Microbiology and Immunology at Faculty of Medicine, University of Leicester. Then started to work as a postdoc with Professor Wilhelm Schwaeble. Since that time, my major research focused on the role of complement system in health and disease.






Complement is an essential part of innate immune system that plays major role in protection against bacterial infection and clearance of host dead cells. On the other hand, Complement activation was also associated with inflammatory disorders such as ischemia reperfusion injury (IRI), Hemolytic uremic syndrome (HUS), multiple sclerosis (MS) and renal diseases. Based on that my research interest focuses on: 

i. The role and contribution of complement activation in pathophysiology of pathological disorders such as IRI, HUS, MS 

ii. Production of recombinant molecules and low molecular weight inhibitors that can be used as new therapeutic approaches 

iii. The role of complement activation and innate immunity in protection against bacterial infection and how bacteria develop mechanisms to evade complement attack.



Key publications: 

(1) Abd El-Aziz AM, Elgaml A, Ali YM. Bacteriophage therapy increases complement mediated lysis of bacteria and enhances bacterial clearance after acute lung infection with MDR Pseudomonas aeruginosa. J Infect Dis 2018 Nov 22.

(2) Ali YM, Abd El-Aziz AM, Mabrook M, Shabaan AA, Sim RB, Hassan R. Recombinant chemotaxis inhibitory protein of Staphylococcus aureus (CHIPS) protects against LPS-induced lung injury in mice. Clin Immunol 2018 Aug 23;197:27-33.

(3) Haleem KS, Ali YM, Yesilkaya H, Kohler T, Hammerschmidt S, Andrew PW, et al. The Pneumococcal Surface Proteins PspA and PspC Sequester Host C4-Binding Protein To Inactivate Complement C4b on the Bacterial Surface. Infect Immun 2018 Dec 19;87(1):10.1128/IAI.00742-18. Print 2019 Jan.

 (4) Ali YM, Hayat A, Saeed BM, Haleem KS, Alshamrani S, Kenawy HI, et al. Low-dose recombinant properdin provides substantial protection against Streptococcus pneumoniae and Neisseria meningitidis infection. Proc Natl Acad Sci U S A 2014 Apr 8;111(14):5301-5306.

 (5) Ali YM, Lynch NJ, Haleem KS, Fujita T, Endo Y, Hansen S, et al. The lectin pathway of complement activation is a critical component of the innate immune response to pneumococcal infection. PLoS Pathog 2012;8(7):e1002793.

(6) Schwaeble WJ, Lynch NJ, Clark JE, Marber M, Samani NJ, Ali YM, et al. Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury. Proc Natl Acad Sci U S A 2011 May 3;108(18):7523-7528.

Research Associate
Not available for consultancy


Person keywords: 
Autoimmune diseases
Complement system
Bacterial infection